



Eli Lilly and Co / LLY

Equity | Generated Oct 9, 2026 11:31 PM EDT

Current price	Daily move	Bid / Ask	Previous close
\$1,177.05	+7.45 +0.64%	-/-	\$1,169.60

Market	NYSE
Industry	Pharmaceuticals
Market data as of	Oct 9, 2026 11:31 PM EDT

JW Intelligence Report

Complete | 3 of 3 sections | Oct 9, 2026 7:50 PM EDT

JW Rank	Rank label	Confidence	IV percentile
81.2 / 100	Strong setup	high	78 / 100
Model reference	Upside scenario	Risk reference	Wheel strategy fit
\$1,165.00	\$1,230.00	\$1,125.00	85 / 100

Options stance	bullish
Tail-risk safety	56 / 100
JW Rank data coverage / as of	100.0% Oct 9, 2026 7:50 PM EDT

Key insight

Lilly Option Market Prices in Continued Growth Potential

Market read

The option market for LLY reflects a bullish outlook, pricing in continued growth potential driven by strong fundamentals and upcoming catalysts. The stock's recent price action has been positive, with the underlying price trading above key moving averages and showing signs of consolidation within an uptrend. While short-term volatility is expected ahead of earnings, the overall market sentiment suggests optimism for LLY's future performance.

Strategy context

The option market suggests investors are positioning for continued upside in LLY, with call buying outweighing put buying. This bullish sentiment is likely driven by the company's strong fundamentals and upcoming catalysts.



JW AI conclusions

Short- and medium-term model interpretation

AI context bias

Mixed

AI analysis updated

Oct 9, 2026 2:11 PM EDT

Short-term scenario

Cautious buy on weakness, not a chase. Prefer scaling in only if price holds the \$1,155-\$1,170 area ahead of the Oct 29 earnings binary; reduce size into the print because a guidance or Foundayo surprise can gap through nearby levels. Levels are tactical, not a forecast, and this is not advice to use leverage.

Three-month outlook

Moderately bullish base case with a wide range. If Q3 confirms incretin volume, Medicare bridge uptake, and stable or improving Foundayo trends, a drift toward the Street cluster near \$1,300-\$1,340 (low-to-mid teens upside from about \$1,176) is plausible over three months, but that is an analyst average, not a forecast. A miss on pricing, oral share, or a conservative guide could retest \$1,100-\$1,130. Pipeline items (retatrutide BLA timing in Q1 2027 and combo data) support the medium-term story but are unlikely to be fully priced in three months. Key uncertainties: weekly script data can reverse; the forward multiple still embeds high growth; Novo and later entrants remain competitive; and Oct 29 can reset the path. Not investment advice.

Market sentiment

Mixed and noisy. Much of the latest \$LLY keyword flow is promotional spam and should be discounted. More substantive posts are cautiously constructive: analyst-target raises (Cantor Overweight, PT \$1,440) and interest in next-gen obesity data, including early eloralintide-plus-tirzepatide efficacy signals and retatrutide. Offsetting that, traders flag a rich multiple near 38x trailing earnings, crowded GLP-1 competition, and a cited weekly drop in Foundayo prescriptions versus stable oral Wegovy. One technical post argued weakening momentum with a downside objective near \$1,098, an outlier versus the prevailing hold-above-\$1,130 tape. Net read: not euphoric; focus is Oct 29 earnings and whether oral share stabilizes. Uncertainty: X samples are small, bot-skewed, and not a reliable positioning gauge.

Supporting evidence

LLY's option chain displays a bullish skew, with call options more expensive than put options. | Implied volatility is elevated, suggesting anticipation of significant price movement around upcoming events like Q3 earnings and potential regulatory approvals. | The term structure shows a contango pattern, indicating market expectations for future price increases.


Risk watch

Earnings results on October 29th could significantly impact the stock price, both positively and negatively.



Enhanced price structure

45 trading days with volume, model levels and current technical reference bands



45 complete trading-session observations



JW Rank factors

Score, source coverage and interpretation for each decision factor



Decision summary

Primary model reads before the detailed indicator appendix

Momentum

strong_bull

Institutional flow

Above MVWAP

Structure

Above 200D trend

Volatility

medium



Decision indicators

Detailed momentum, institutional and structural observations

Momentum kinematics

Direction, velocity and oscillator state

Current read	STRONG BULL neutral MACD accelerating
Trend signal	STRONG BULL
RSI signal	neutral
RSI (7 / 14 / 21)	58.67 / 54.21 / 52.57
RSI velocity	1.93
MACD line / signal / histogram	0.76 / - / -2.05
MACD acceleration	1.56
Stochastic K / D	56.86 / 46.80

Institutional footprints

Volume-weighted cost, price location and flow

Current read	Above institutional MVWAP Accumulation bias
Institutional flow	2.28
20-day MVWAP	\$1,162.60
Price vs 20-day MVWAP	+1.24%
Daily reference VWAP	\$1,170.25
Price vs daily reference	+0.58%
Volume	687.87K

Structural context

Long-term trend and volatility boundaries

Current read	Above 200-day trend Positive macro velocity
Macro velocity	2.91
20-day / 200-day SMA	\$1,161.32 / \$1,076.50
Bollinger range	\$1,125.63 - \$1,197.01
Bollinger position	0.752



Options and volatility intelligence


Structure, premium conditions and principal risks

IV rank	IV percentile	VVIX	SKEW
68 / 100	79 / 100	86.15	149.19

Market regime	Calm
Tail-risk regime	NORMAL TAIL RISK
Term structure	contango
Term slope	+15.02 pts
Skew read	balanced
Liquidity / quote coverage	100.0%
Options Snapshot IV sources	ATM: option chain Rank/percentile: fundamentals
Options Snapshot IV observed at	Oct 9, 2026 2:53 PM EDT
Options data quality	Coverage 77.8%

Option term structure

ATM implied-volatility curve by days to expiration



EXPIRATION	DTE	ATM IV	STATE
2026-10-16	7	29.9%	-
2026-10-23	14	30.6%	-
2026-10-30	21	44.9%	-



Event and tail-risk context

Known event windows and broad volatility conditions

Next earnings date	2026-10-29
Earnings IV-crush risk	unknown
VIX	14.87
VVIX	86.15
SKEW index	149.19
Observation confidence	medium
Option quote quality	reliable
Contracts observed	112
Contracts with quotes	112

Strategy fit

Generalized structure fit; not a personalized recommendation

Market structure

The option market for LLY reflects a bullish outlook, pricing in continued growth potential driven by strong fundamentals and upcoming catalysts. The stock's recent price action has been positive, with the underlying price trading above key moving averages and showing signs of consolidation within an uptrend. While short-term volatility is expected ahead of earnings, the overall market sentiment suggests optimism for LLY's future performance.

Options context

Lilly Option Market Prices in Continued Growth Potential

Wheel context

The option market suggests investors are positioning for continued upside in LLY, with call buying outweighing put buying. This bullish sentiment is likely driven by the company's strong fundamentals and upcoming catalysts.

Observed evidence

LLY's option chain displays a bullish skew, with call options more expensive than put options. | Implied volatility is elevated, suggesting anticipation of significant price movement around upcoming events like Q3 earnings and potential regulatory approvals. | The term structure shows a contango pattern, indicating market expectations for future price increases.

Principal risks to monitor

Earnings results on October 29th could significantly impact the stock price, both positively and negatively.



Fundamentals and events

Business quality, valuation and upcoming event context

Market capitalization	P/E (TTM)
\$1.10T	41.01
ROE	Revenue growth
92.6%	31.7%
EPS growth	Operating margin
49.3%	42.2%
Net profit margin	Gross margin
33.5%	-
Free cash flow CAGR	Debt / equity
5.9%	1.60
Dividend yield	Beta
0.8%	0.42
52-week range	
\$783.85 - \$1,292.65	

Company or fund profile

Issuer identity and classification

Name	Market
Eli Lilly and Co	NYSE
Industry	Country
Pharmaceuticals	US
Currency	IPO date
USD	1970-07-09
Shares outstanding	52-week return
941.74M	40.9%
Book value per share	Revenue per share
\$35.98	\$89.14
Website	
	lilly.com



Latest strategy observation

Most recent shared general market signal available when this report was generated

LLY Covered Call signal

Covered Call | 2026-10-16

At signal \$1,171.11 | Current \$1,177.05

SHORT Option \$1,175.00 B \$17.20 / A \$19.80

Conservative | CR \$18.50

Oct 9, 2026 11:24 AM EDT



Complete technical details

Full supporting indicator set used by the symbol detail experience

Volatility and options market

Price movement and premium conditions

ATR	\$34.41
ATR as % of price	2.9%
Volatility environment	medium
Current IV	40.8%
IV rank	67 / 100
IV percentile	78 / 100
Technical Snapshot IV source	Private fundamentals snapshot
Technical Snapshot IV observed at	Oct 9, 2026 3:50 PM EDT

Technical health and risk radar

Derived indicator health and event context

Overall health	85 / 100
Trend health	92 / 100
Momentum health	99 / 100
Volatility health	66 / 100
Structure health	75 / 100
Earnings risk / date	medium 2026-10-29
Macro risk	unknown
Volatility risk	medium
Structure risk	low

Structural indicator levels

Moving averages, volatility bands and observed trading ranges

SMA (20 / 50 / 200)	\$1,161.32 / \$1,173.97 / \$1,076.50
EMA (9 / 21)	\$1,167.50 / \$1,164.91
Bollinger upper / middle / lower	\$1,197.01 / \$1,161.32 / \$1,125.63



Structural indicator levels (continued)

Moving averages, volatility bands and observed trading ranges

FIELD	VALUE
Bollinger %B	0.752
True high / low	\$1,179.82 / \$1,151.67
5-day true high / low	\$1,206.63 / \$1,131.21

Three-day indicator history

Short-horizon change and the underlying three-session observations

INDICATOR	3-DAY CHANGE	SESSION 1 / 2 / 3
SMA20	2.911	-
SMA50	-0.320	-
MVWAP20	2.278	-
MACD	1.562	-
RSI	1.929	-
Volume	-134933.670	-
ATR	0.830	-
T1	-	-0.52 / 1160.84 / 1188.72 / 1131.21
T2	-	-1.17 / 1159.09 / 1206.63 / 1157.49
T3	-	-3.92 / 1155.76 / 1177.07 / 1139.98



Detailed options evidence

Supporting option-chain, execution and data-quality observations

Underlying price at observation	\$1,175.18
Options Snapshot IV sources	ATM: option chain Rank/percentile: fundamentals
Options Snapshot IV observed at	Oct 9, 2026 2:53 PM EDT
Options data coverage	77.8%
SKEW regime	HIGH TAIL RISK SKEW
VVIX regime	VVIX FLAT
Front expiration / DTE	2026-10-16 7 DTE
Front at-the-money IV	29.9%
25-delta skew	1.67
Put / Call 25-delta	\$1,145.00 Delta -0.259 / \$1,205.00 Delta 0.285
Median option bid/ask spread	17.6%
Bid/ask spread	-
Contracts observed / quoted	112 / 112

Price context

Last Price: 1,175.18 | Bid: 1,174.54 | Ask: 1,175.67 | Previous Close: 1,169.60 | Change: 5.58 | Daily change: 0.48% | Update Time: 2026-10-09T14:53:18.787994-04:00 | Latest History Date: 2026-10-09 | Latest History Price: 1,175.17

Historical context

Trading-day sample: 60 sessions | First Date: 2026-07-17 | Latest Date: 2026-10-09 | Latest Price: 1,175.17 | Max Drawdown 60d Percent: -12.86%

Fundamental context

Current Iv Percent: 40.96% | Iv Rank: 67.72 | Iv Percentile: 79.28 | Next Earnings Date: 2026-10-29 | Ex Dividend Date: 2026-08-13



Important disclosures

Scope, limitations, risk and permitted interpretation

General market information only

This report is general quantitative research and market commentary. It is not investment, legal, tax or accounting advice; it is not an offer, solicitation, order, recommendation or promise of performance. It does not consider any reader's holdings, objectives, financial circumstances, risk tolerance or suitability.

Model observations - not instructions

JW Rank, strategy fit, model reference, upside scenario and risk reference levels are model observations. They are not entries, price targets, stops, position sizes or instructions to buy, sell, open, close or hold a security or option. A higher score does not imply lower risk or a guaranteed favorable outcome.

Data, AI and model limitations

Prices, volumes, fundamentals, options data, news-derived context and model outputs reflect the timestamps shown and may be delayed, incomplete, revised or inaccurate. AI-generated explanations can omit context or produce errors. Models can fail when volatility, liquidity, correlations or market regimes change.

Performance and scenario limitations

Past, hypothetical, back-tested, simulated and model-derived results are not indicative of future results. Strategy statistics may exclude commissions, fees, taxes, slippage, early assignment, execution constraints and other costs unless expressly stated. Actual outcomes may differ materially.

Options risk

Options are complex and are not suitable for all investors. They may involve total or substantial loss, assignment, early exercise, margin calls, liquidity and spread risk, volatility and Greek exposure, event risk, regime shifts and expiration risk. Multi-leg positions may not execute or close at modeled prices.

Investor responsibility and ODD

Use current market information, assess suitability independently and consult qualified professionals when appropriate. Before trading listed options, read Characteristics and Risks of Standardized Options (ODD) available from the Options Clearing Corporation at theocc.com.

Generated Oct 9, 2026 11:31 PM EDT. Jason Wheel Terms of Use and Privacy Policy apply. Copyright Jason Wheel Research LLC. All rights reserved.

Reference documents

Official product terms and standardized options disclosure

Jason Wheel	jasonwheel.com
Terms of Use	jasonwheel.com / Terms
Privacy Policy	jasonwheel.com / Privacy
Options Disclosure Document	theocc.com / Options Disclosure Document